Vimarsana
Biggest News Aggregation in the World

Page 8 - Sciences Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sciences Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sciences Group Today - Breaking & Trending Today

Investegate | Company Announcement - Vimarsana News

Investegate | Company Announcement

Investegate announcements from Placing and Subscription

SELLAS Life Sciences Group, Inc. to Post FY2023 Earnings of ($1.04) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:SLS) - Vimarsana News

SELLAS Life Sciences Group, Inc. to Post FY2023 Earnings of ($1.04) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Free Report) – Investment analysts at Cantor Fitzgerald lowered their FY2023 earnings per share estimates for SELLAS Life Sciences Group in a research report issued to clients and investors on Monday, November 13th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings of ($1.04) […]

Source: wkrb13.com
SELLAS Life Sciences Group Inc (SLS) Shares Decline Despite Market Challenges - Vimarsana News

SELLAS Life Sciences Group Inc (SLS) Shares Decline Despite Market Challenges

The stock of SELLAS Life Sciences Group Inc (NASDAQ: SLS) has decreased by -2.70 when compared to last closing price of 0.91.Despite this, the company has seen a loss of -8.53% in its stock price over the last five trading days. GlobeNewsWire reported 2023-10-17 that NEW YORK, Oct. 17, 2023 (GLOBE N

SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, ... - Vimarsana News

SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, ...

– FDA feedback indicates Company’s CMC plans are in alignment with FDA’s requirements and expectations towards a BLA –

SELLAS Life Sciences Presents Positive Key Immunobiological - Vimarsana News

SELLAS Life Sciences Presents Positive Key Immunobiological

Median overall survival for GPS and Keytruda® combination was 18.4 Months compared to 13.8 Months in a Keytruda® single agent study (KEYNOTE-028) and 11-14...